Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.


Sci. Signal., 6 November 2012
Vol. 5, Issue 249, p. pc25
[DOI: 10.1126/scisignal.2003723]


Science Signaling Podcast: 6 November 2012

Michael A. Frohman1 and Annalisa M. VanHook2

1 Department of Pharmacological Sciences, Center for Developmental Genetics, and Graduate Program in Molecular and Cellular Pharmacology, Stony Brook University, Stony Brook, NY 11794–5140, USA.
2 Web Editor, Science Signaling, American Association for the Advancement of Science, 1200 New York Avenue, NW, Washington, DC 20005, USA.

Abstract: This is an interview with Michael Frohman, senior author of a Research Article that appears in this issue of Science Signaling. Frohman’s group has investigated the role of the enzyme phospholipase D1 (PLD1) in the tumor microenvironment. PLD1 produces the lipid phosphatidic acid, which acts as a second messenger in many signaling pathways and promotes proliferation, survival, and metastasis of cancer cells. When tumor cells were implanted into mice lacking PLD1, the resulting tumors were smaller and less vascularized than those that developed in wild-type mice and produced fewer lung metastases. Treating wild-type mice with a PLD1 inhibitor also inhibited tumor growth and metastasis, suggesting that inhibiting the activity of PLD1 might be a useful approach for treating human cancers.

Citation: M. A. Frohman, A. M. VanHook, Science Signaling Podcast: 6 November 2012. Sci. Signal. 5, pc25 (2012).

Read the Full Text

To Advertise     Find Products

Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882